Abstract
Posaconazole is an attractive agent for fungal prophylaxis in lung transplant patients due to its broad spectrum of activity. The oral suspension (POS) formulation has poor bioavailability requiring low pH and dietary fat for adequate systemic exposure. In November 2013 the FDA approved a posaconazole extended-release tablet (PERT) formulation. Given its more predictable absorption and systemic exposure, we transitioned to the use of the new formulation. The aim of this study is to compare the likelihood of achieving therapeutic posaconazole levels (≥0.7 mg/L) using the two oral formulations of posaconazole.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
